Cohort Study Evaluating Glycaemic Control in Individuals with Type 2 Diabetes Mellitus Through Digital Therapeutics (DM DTx)
Launched by EVYD TECHNOLOGY · Jan 31, 2025
Trial Information
Current as of November 10, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying how well digital tools can help people with Type 2 Diabetes manage their condition. The research focuses on using a national health app called BruHealth to offer lifestyle tips and support to improve blood sugar control. The trial is currently looking for participants aged 18 to 70 who have been diagnosed with Type 2 Diabetes and are receiving treatment, whether that's through medication, insulin (up to two injections a day), diet control, or a specific type of medication called GLP-1 receptor agonists.
If you join the study, you'll get access to the digital program through BruHealth, which aims to guide you in making healthier lifestyle choices. However, there are some important requirements: you shouldn't be using more than two insulin injections daily, have certain serious health conditions, or require help with daily activities. This trial offers a chance to explore how technology can support your diabetes management, and your participation could help improve care for others in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Age 18 to 70 years
- * Diagnosed with T2DM who are on any one or more of the following treatments:
- • 1. oral glucose lowering medication(s)
- • 2. any type of insulin treatment (up to 2 injections a day only)
- • 3. on diet control only
- • 4. GLP-1 receptor agonist established at least 6 months prior to enrolment
- Exclusion Criteria:
- • Diagnosed with T2DM on more than 2 insulin injections a day
- • Diagnosed with Type 1 Diabetes Mellitus (T1DM)
- • Pregnant / Breast-feeding
- • Recent Myocardial Infarction (MI) or Stroke / Cerebrovascular Accidents (CVA) in the past 6 months
- • Heart failure
- • Liver failure
- • Active cancer
- • Undergoing active treatment for active foot disease
- • Undergoing active treatment for active diabetes-related eye disease
- • CKD stage 4 and 5 (eGFR \< 30ml/min)
- • Hospitalisation for any reason in the past 6 months
- • Advised by doctor to not participate in intense physical activity
- • Physical disability and/or unable to perform Activities of Daily Living (ADL) independently
- • Unable to use Youtube on mobile devices
- • Unable to use BruHealth independently
About Evyd Technology
Evyd Technology is a pioneering clinical trial sponsor dedicated to advancing medical research through innovative technology solutions. By leveraging cutting-edge data analytics and digital tools, Evyd enhances the efficiency and effectiveness of clinical trials, ensuring robust patient engagement and streamlined operations. Committed to transparency and ethical practices, the organization collaborates closely with healthcare professionals, regulatory bodies, and research institutions to deliver high-quality, actionable insights that accelerate drug development and improve patient outcomes. With a strong focus on patient-centric approaches, Evyd Technology is redefining the landscape of clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bandar Seri Begawan, Brunei Darussalam
Patients applied
Trial Officials
Chong Pui Lin, BM, MD
Principal Investigator
Raja Isteri Pengiran Anak Saleha (RIPAS) hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported